Follicular Lymphoma clinical trials

Explore recruiting follicular lymphoma clinical trials.

Recruiting follicular lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Follicular Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II trial investigating MOsunetuzumab and ZAnubrutinib (BGB-3111) in Relapsed/refracTory follicular lymphoma patients (MOZART)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Italy, Greece, Austria, Netherlands, Hungary, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2)

Czechia, Belgium, Italy, Spain, France, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7

Finland, Denmark, Iceland, Norway, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma as primary treatment: a phase II study – NLG-FL5 (Follicular lymphoma and ME-401: FLAME)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Follicular Lymphoma trials by city

Follicular Lymphoma in Toronto Follicular Lymphoma in Vancouver Follicular Lymphoma in Montreal Follicular Lymphoma in Calgary Follicular Lymphoma in Edmonton Follicular Lymphoma in Ottawa Follicular Lymphoma in Winnipeg Follicular Lymphoma in Quebec City Follicular Lymphoma in Hamilton Follicular Lymphoma in Kitchener Follicular Lymphoma in London Follicular Lymphoma in Halifax Follicular Lymphoma in New York Follicular Lymphoma in Los Angeles Follicular Lymphoma in Chicago Follicular Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease